Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 92 | 2024 | 4916 | 6.370 |
Why?
|
Phthalazines | 16 | 2024 | 397 | 3.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 54 | 2024 | 11878 | 2.370 |
Why?
|
Neoplasm Recurrence, Local | 48 | 2024 | 9419 | 2.140 |
Why?
|
Genital Neoplasms, Female | 7 | 2022 | 536 | 1.700 |
Why?
|
Paclitaxel | 30 | 2023 | 1733 | 1.600 |
Why?
|
Peritoneal Neoplasms | 14 | 2021 | 714 | 1.250 |
Why?
|
Piperazines | 14 | 2024 | 2554 | 1.200 |
Why?
|
Fallopian Tube Neoplasms | 10 | 2015 | 329 | 1.170 |
Why?
|
Mixed Tumor, Mullerian | 7 | 2009 | 55 | 1.100 |
Why?
|
Carboplatin | 18 | 2023 | 797 | 1.090 |
Why?
|
Physician-Patient Relations | 17 | 2014 | 3269 | 0.940 |
Why?
|
Topotecan | 13 | 2023 | 131 | 0.940 |
Why?
|
Genes, BRCA1 | 6 | 2021 | 755 | 0.930 |
Why?
|
Endometrial Neoplasms | 7 | 2022 | 1382 | 0.920 |
Why?
|
Genes, BRCA2 | 5 | 2021 | 593 | 0.830 |
Why?
|
Neutropenia | 3 | 2023 | 892 | 0.820 |
Why?
|
Uterine Cervical Neoplasms | 11 | 2023 | 2043 | 0.770 |
Why?
|
Cyclodextrins | 1 | 2021 | 63 | 0.740 |
Why?
|
Antineoplastic Agents | 27 | 2024 | 13676 | 0.700 |
Why?
|
Carcinoma | 6 | 2015 | 2332 | 0.700 |
Why?
|
Organoplatinum Compounds | 9 | 2020 | 408 | 0.670 |
Why?
|
Camptothecin | 2 | 2021 | 600 | 0.670 |
Why?
|
Neoplasms | 24 | 2024 | 22371 | 0.660 |
Why?
|
Platinum Compounds | 3 | 2020 | 95 | 0.650 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2013 | 218 | 0.650 |
Why?
|
Caregivers | 17 | 2014 | 2302 | 0.610 |
Why?
|
Morphine Derivatives | 3 | 2002 | 43 | 0.580 |
Why?
|
Quality of Life | 22 | 2023 | 13490 | 0.540 |
Why?
|
Phenylurea Compounds | 1 | 2020 | 531 | 0.540 |
Why?
|
Quinazolines | 4 | 2024 | 1373 | 0.530 |
Why?
|
Female | 149 | 2024 | 397192 | 0.530 |
Why?
|
Disease-Free Survival | 16 | 2023 | 6847 | 0.520 |
Why?
|
Drug Administration Schedule | 19 | 2021 | 4860 | 0.520 |
Why?
|
Carcinoma, Small Cell | 6 | 2010 | 419 | 0.510 |
Why?
|
Therapeutic Equipoise | 1 | 2015 | 29 | 0.500 |
Why?
|
Folate Receptor 1 | 2 | 2020 | 41 | 0.500 |
Why?
|
Vinca Alkaloids | 2 | 2014 | 36 | 0.490 |
Why?
|
Patient-Centered Care | 4 | 2014 | 1444 | 0.490 |
Why?
|
Germ-Line Mutation | 5 | 2024 | 1885 | 0.460 |
Why?
|
Quinolines | 1 | 2020 | 772 | 0.460 |
Why?
|
Attitude to Death | 4 | 2007 | 400 | 0.460 |
Why?
|
Humans | 184 | 2024 | 768166 | 0.440 |
Why?
|
Hydroxamic Acids | 4 | 2015 | 483 | 0.440 |
Why?
|
Drug Resistance, Neoplasm | 17 | 2024 | 5341 | 0.440 |
Why?
|
Antineoplastic Agents, Phytogenic | 8 | 2012 | 622 | 0.440 |
Why?
|
Uterine Hemorrhage | 2 | 2013 | 236 | 0.430 |
Why?
|
Professional-Patient Relations | 6 | 2010 | 724 | 0.420 |
Why?
|
Angiogenesis Inhibitors | 8 | 2023 | 2056 | 0.420 |
Why?
|
Medical Oncology | 8 | 2006 | 2346 | 0.420 |
Why?
|
Carcinosarcoma | 1 | 2013 | 108 | 0.400 |
Why?
|
Middle Aged | 91 | 2024 | 223492 | 0.400 |
Why?
|
Aged | 79 | 2024 | 171504 | 0.390 |
Why?
|
Neoplasms, Glandular and Epithelial | 4 | 2011 | 489 | 0.380 |
Why?
|
Pain | 7 | 2014 | 5100 | 0.380 |
Why?
|
Octreotide | 2 | 2005 | 156 | 0.370 |
Why?
|
Palliative Care | 13 | 2011 | 3643 | 0.360 |
Why?
|
Cisplatin | 11 | 2023 | 1660 | 0.360 |
Why?
|
Combined Modality Therapy | 12 | 2021 | 8542 | 0.350 |
Why?
|
Endometrium | 1 | 2013 | 406 | 0.350 |
Why?
|
Adult | 81 | 2024 | 223646 | 0.340 |
Why?
|
Cystadenocarcinoma, Serous | 3 | 2020 | 480 | 0.340 |
Why?
|
Deoxycytidine | 7 | 2024 | 887 | 0.340 |
Why?
|
Drug Therapy | 1 | 2013 | 504 | 0.330 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 662 | 0.330 |
Why?
|
Infusions, Intravenous | 12 | 2020 | 2230 | 0.330 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2022 | 2885 | 0.310 |
Why?
|
Vulvar Neoplasms | 2 | 2001 | 266 | 0.310 |
Why?
|
Terminal Care | 4 | 2020 | 1770 | 0.300 |
Why?
|
Acupuncture Therapy | 2 | 2010 | 486 | 0.300 |
Why?
|
Folic Acid | 2 | 2014 | 1337 | 0.300 |
Why?
|
Antibodies, Monoclonal | 7 | 2022 | 9263 | 0.290 |
Why?
|
Aged, 80 and over | 25 | 2024 | 59629 | 0.290 |
Why?
|
Patient Care Team | 4 | 2010 | 2523 | 0.280 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 1 | 2009 | 117 | 0.280 |
Why?
|
Doxorubicin | 10 | 2020 | 2234 | 0.280 |
Why?
|
BRCA1 Protein | 5 | 2022 | 1155 | 0.280 |
Why?
|
CA-125 Antigen | 3 | 2020 | 281 | 0.270 |
Why?
|
Communication | 8 | 2011 | 3905 | 0.270 |
Why?
|
Sickness Impact Profile | 2 | 2010 | 299 | 0.270 |
Why?
|
Blood Transfusion | 2 | 2004 | 1309 | 0.260 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 892 | 0.260 |
Why?
|
Progestins | 1 | 2008 | 302 | 0.260 |
Why?
|
Laughter Therapy | 1 | 2005 | 3 | 0.260 |
Why?
|
Hemangiosarcoma | 1 | 2008 | 215 | 0.260 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3706 | 0.250 |
Why?
|
Indoles | 3 | 2024 | 1836 | 0.250 |
Why?
|
Pyrroles | 2 | 2012 | 1124 | 0.250 |
Why?
|
Uterine Neoplasms | 3 | 2013 | 1424 | 0.250 |
Why?
|
Wit and Humor as Topic | 1 | 2005 | 31 | 0.250 |
Why?
|
Glucuronides | 1 | 2005 | 20 | 0.250 |
Why?
|
Survival Rate | 10 | 2020 | 12840 | 0.250 |
Why?
|
Isoxazoles | 2 | 2024 | 233 | 0.240 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2004 | 56 | 0.240 |
Why?
|
Survivors | 4 | 2011 | 2381 | 0.240 |
Why?
|
Jehovah's Witnesses | 1 | 2004 | 13 | 0.230 |
Why?
|
Physician's Role | 2 | 2002 | 925 | 0.230 |
Why?
|
Immunotherapy | 2 | 2020 | 4755 | 0.230 |
Why?
|
Truth Disclosure | 3 | 2006 | 434 | 0.230 |
Why?
|
Clinical Trials as Topic | 8 | 2020 | 8054 | 0.230 |
Why?
|
Freedom | 1 | 2004 | 69 | 0.220 |
Why?
|
Treatment Refusal | 3 | 2004 | 433 | 0.220 |
Why?
|
Neoplasm Staging | 15 | 2017 | 11244 | 0.220 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 498 | 0.220 |
Why?
|
Metaphor | 1 | 2004 | 41 | 0.220 |
Why?
|
Adolescent Development | 1 | 2007 | 276 | 0.220 |
Why?
|
Platinum | 3 | 2020 | 222 | 0.220 |
Why?
|
Treatment Outcome | 25 | 2024 | 65371 | 0.220 |
Why?
|
Burnout, Professional | 3 | 2003 | 711 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2017 | 10399 | 0.220 |
Why?
|
Analgesics, Opioid | 4 | 2005 | 3837 | 0.220 |
Why?
|
Morphine | 2 | 2005 | 658 | 0.210 |
Why?
|
Tablets | 2 | 2021 | 149 | 0.210 |
Why?
|
Intestinal Obstruction | 2 | 2011 | 433 | 0.210 |
Why?
|
Oncology Service, Hospital | 1 | 2003 | 56 | 0.210 |
Why?
|
bcl-X Protein | 1 | 2024 | 412 | 0.200 |
Why?
|
Self-Help Groups | 1 | 2004 | 194 | 0.200 |
Why?
|
Identity Crisis | 1 | 2002 | 12 | 0.200 |
Why?
|
Biomedical Research | 1 | 2018 | 3463 | 0.200 |
Why?
|
Kaplan-Meier Estimate | 7 | 2020 | 6526 | 0.200 |
Why?
|
Faith Healing | 1 | 2002 | 26 | 0.200 |
Why?
|
Prejudice | 2 | 2004 | 574 | 0.190 |
Why?
|
Complementary Therapies | 2 | 2008 | 487 | 0.190 |
Why?
|
Pyrimidinones | 1 | 2024 | 386 | 0.190 |
Why?
|
Molecular Targeted Therapy | 5 | 2020 | 2830 | 0.190 |
Why?
|
Sulfonamides | 4 | 2024 | 1982 | 0.190 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2008 | 364 | 0.190 |
Why?
|
Adaptation, Psychological | 7 | 2010 | 2663 | 0.190 |
Why?
|
Health Services for the Aged | 1 | 2004 | 264 | 0.180 |
Why?
|
Mental Healing | 1 | 2001 | 28 | 0.180 |
Why?
|
Attitude to Health | 2 | 2007 | 2025 | 0.180 |
Why?
|
BRCA2 Protein | 4 | 2022 | 802 | 0.180 |
Why?
|
Medication Adherence | 1 | 2013 | 2187 | 0.180 |
Why?
|
Survival Analysis | 12 | 2023 | 10101 | 0.180 |
Why?
|
Religion | 2 | 2002 | 376 | 0.180 |
Why?
|
Lung Neoplasms | 10 | 2005 | 13586 | 0.180 |
Why?
|
Pyrazines | 2 | 2024 | 1205 | 0.180 |
Why?
|
Ethics, Medical | 4 | 2002 | 785 | 0.180 |
Why?
|
Analgesia | 1 | 2005 | 460 | 0.180 |
Why?
|
Information Services | 1 | 2002 | 239 | 0.180 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2016 | 905 | 0.170 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 431 | 0.170 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 257 | 0.170 |
Why?
|
Menopause | 1 | 2008 | 1656 | 0.170 |
Why?
|
Cell Cycle | 1 | 2008 | 2932 | 0.170 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2001 | 737 | 0.170 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2021 | 254 | 0.160 |
Why?
|
Bleomycin | 1 | 2020 | 492 | 0.160 |
Why?
|
Lymphatic Metastasis | 3 | 2001 | 2914 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 819 | 0.150 |
Why?
|
Vinblastine | 1 | 2020 | 487 | 0.150 |
Why?
|
Mutation | 9 | 2024 | 30238 | 0.150 |
Why?
|
Aniline Compounds | 1 | 2024 | 1094 | 0.150 |
Why?
|
Patient Advocacy | 1 | 2001 | 362 | 0.150 |
Why?
|
Empathy | 3 | 2010 | 474 | 0.150 |
Why?
|
Antineoplastic Protocols | 1 | 2018 | 48 | 0.150 |
Why?
|
Sexuality | 1 | 2000 | 179 | 0.150 |
Why?
|
Trust | 1 | 2003 | 532 | 0.150 |
Why?
|
Prognosis | 14 | 2021 | 30010 | 0.140 |
Why?
|
Bereavement | 1 | 2002 | 310 | 0.140 |
Why?
|
History, 18th Century | 1 | 2018 | 206 | 0.140 |
Why?
|
Osteoarthropathy, Secondary Hypertrophic | 1 | 1997 | 13 | 0.140 |
Why?
|
Transgenes | 1 | 2021 | 1016 | 0.140 |
Why?
|
Stress, Psychological | 6 | 2010 | 4530 | 0.140 |
Why?
|
Receptors, Progesterone | 3 | 2013 | 1160 | 0.140 |
Why?
|
Pancreatic Neoplasms | 2 | 2014 | 5446 | 0.140 |
Why?
|
Women's Health | 1 | 2006 | 2082 | 0.140 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2001 | 4058 | 0.140 |
Why?
|
Parent-Child Relations | 1 | 2002 | 772 | 0.140 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 368 | 0.140 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2019 | 195 | 0.140 |
Why?
|
Double-Blind Method | 5 | 2024 | 12465 | 0.140 |
Why?
|
Salvage Therapy | 2 | 2020 | 1273 | 0.140 |
Why?
|
Adenoviridae | 1 | 2021 | 1092 | 0.140 |
Why?
|
Adenocarcinoma | 5 | 2017 | 6395 | 0.130 |
Why?
|
Recurrence | 4 | 2023 | 8509 | 0.130 |
Why?
|
Attitude of Health Personnel | 5 | 2006 | 3929 | 0.130 |
Why?
|
Pleural Effusion | 1 | 1999 | 344 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2005 | 5432 | 0.130 |
Why?
|
Germ Cells | 1 | 2020 | 644 | 0.130 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1767 | 0.130 |
Why?
|
Cystadenoma, Serous | 1 | 2016 | 100 | 0.130 |
Why?
|
Injections, Subcutaneous | 3 | 2009 | 687 | 0.130 |
Why?
|
Fear | 1 | 2005 | 1495 | 0.130 |
Why?
|
Genetic Counseling | 1 | 2000 | 635 | 0.130 |
Why?
|
Leukemia | 1 | 2004 | 1519 | 0.130 |
Why?
|
Breast Neoplasms | 7 | 2022 | 21206 | 0.130 |
Why?
|
Hysterectomy | 2 | 2013 | 863 | 0.130 |
Why?
|
Withholding Treatment | 1 | 2020 | 620 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2021 | 3556 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 5 | 2024 | 5703 | 0.120 |
Why?
|
History, 19th Century | 1 | 2018 | 714 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2020 | 952 | 0.120 |
Why?
|
Health Education | 1 | 2002 | 1059 | 0.120 |
Why?
|
Fatal Outcome | 2 | 2013 | 1836 | 0.120 |
Why?
|
Etoposide | 3 | 2005 | 639 | 0.120 |
Why?
|
Sirolimus | 1 | 2022 | 1540 | 0.120 |
Why?
|
Patient Selection | 3 | 2011 | 4260 | 0.120 |
Why?
|
Genetic Testing | 2 | 2015 | 3591 | 0.120 |
Why?
|
Drug Hypersensitivity | 2 | 2016 | 923 | 0.120 |
Why?
|
United States Food and Drug Administration | 3 | 2018 | 1673 | 0.110 |
Why?
|
Sesquiterpenes | 2 | 2005 | 175 | 0.110 |
Why?
|
Blood Glucose | 1 | 2009 | 6430 | 0.110 |
Why?
|
Nitriles | 2 | 2013 | 980 | 0.110 |
Why?
|
Maximum Tolerated Dose | 3 | 2015 | 899 | 0.110 |
Why?
|
Triazoles | 2 | 2013 | 904 | 0.110 |
Why?
|
Counseling | 1 | 2002 | 1554 | 0.110 |
Why?
|
Drug Interactions | 3 | 2011 | 1419 | 0.110 |
Why?
|
Patient Education as Topic | 1 | 2004 | 2337 | 0.110 |
Why?
|
Neoplasm Proteins | 4 | 2013 | 3603 | 0.110 |
Why?
|
Leucovorin | 2 | 2014 | 643 | 0.110 |
Why?
|
Central Nervous System Stimulants | 1 | 2001 | 1168 | 0.100 |
Why?
|
Hormones | 1 | 1997 | 866 | 0.100 |
Why?
|
Pathology, Molecular | 1 | 2016 | 329 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2062 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2020 | 10760 | 0.100 |
Why?
|
Ribose | 2 | 2022 | 63 | 0.100 |
Why?
|
Patient Acceptance of Health Care | 2 | 2004 | 3231 | 0.100 |
Why?
|
Administration, Oral | 4 | 2012 | 4030 | 0.100 |
Why?
|
Medical Errors | 1 | 2001 | 1260 | 0.100 |
Why?
|
Hemangioma | 1 | 1997 | 727 | 0.100 |
Why?
|
Panniculitis | 1 | 2012 | 45 | 0.100 |
Why?
|
Receptors, Estrogen | 3 | 2022 | 2253 | 0.100 |
Why?
|
Ascites | 1 | 2013 | 338 | 0.100 |
Why?
|
History, 21st Century | 1 | 2018 | 1573 | 0.100 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2005 | 614 | 0.090 |
Why?
|
Time Factors | 10 | 2018 | 40218 | 0.090 |
Why?
|
Fluorouracil | 3 | 2014 | 1652 | 0.090 |
Why?
|
Drug Approval | 1 | 2018 | 821 | 0.090 |
Why?
|
Pilot Projects | 4 | 2010 | 8741 | 0.090 |
Why?
|
Social Support | 3 | 2007 | 2193 | 0.090 |
Why?
|
Family Health | 4 | 2003 | 1255 | 0.090 |
Why?
|
Drug Resistance, Multiple | 2 | 2002 | 255 | 0.080 |
Why?
|
History, 20th Century | 1 | 2018 | 2766 | 0.080 |
Why?
|
Ethics, Clinical | 1 | 2010 | 101 | 0.080 |
Why?
|
Aromatase Inhibitors | 1 | 2013 | 519 | 0.080 |
Why?
|
Leiomyosarcoma | 1 | 2013 | 426 | 0.080 |
Why?
|
Injections, Intravenous | 2 | 2002 | 1377 | 0.080 |
Why?
|
Internet | 1 | 2002 | 3110 | 0.080 |
Why?
|
Neoadjuvant Therapy | 3 | 2019 | 2907 | 0.080 |
Why?
|
Diphosphonates | 1 | 2014 | 634 | 0.080 |
Why?
|
Dermatomyositis | 1 | 2012 | 259 | 0.080 |
Why?
|
Boston | 4 | 2008 | 9374 | 0.080 |
Why?
|
Disease Progression | 7 | 2022 | 13671 | 0.080 |
Why?
|
Nausea | 3 | 2018 | 682 | 0.080 |
Why?
|
Psychometrics | 3 | 2010 | 3063 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2003 | 2931 | 0.080 |
Why?
|
Tamoxifen | 1 | 2013 | 966 | 0.080 |
Why?
|
Colorectal Neoplasms | 1 | 2008 | 6974 | 0.080 |
Why?
|
Europe | 1 | 2015 | 3436 | 0.070 |
Why?
|
Polyethylene Glycols | 3 | 2020 | 1196 | 0.070 |
Why?
|
Adolescent | 9 | 2020 | 89169 | 0.070 |
Why?
|
Immunotherapy, Adoptive | 1 | 2018 | 1512 | 0.070 |
Why?
|
Interleukin-8 | 2 | 2002 | 704 | 0.070 |
Why?
|
Patient Participation | 2 | 2007 | 1447 | 0.070 |
Why?
|
Guanine | 1 | 2008 | 280 | 0.070 |
Why?
|
Glutamates | 1 | 2008 | 385 | 0.070 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2013 | 820 | 0.070 |
Why?
|
Hypercalcemia | 1 | 2010 | 424 | 0.070 |
Why?
|
Proteinuria | 1 | 2010 | 611 | 0.070 |
Why?
|
Osteosarcoma | 3 | 2002 | 911 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2005 | 1536 | 0.070 |
Why?
|
Decision Making | 5 | 2003 | 3953 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2002 | 3626 | 0.060 |
Why?
|
Interprofessional Relations | 3 | 2001 | 997 | 0.060 |
Why?
|
Intestinal Perforation | 1 | 2007 | 254 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2001 | 4310 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3284 | 0.060 |
Why?
|
Hospice Care | 2 | 2003 | 678 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2009 | 1609 | 0.060 |
Why?
|
United States | 7 | 2019 | 73039 | 0.060 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2010 | 778 | 0.060 |
Why?
|
Male | 27 | 2024 | 364719 | 0.060 |
Why?
|
Internship and Residency | 1 | 2005 | 5953 | 0.060 |
Why?
|
Patient Care | 1 | 2010 | 629 | 0.060 |
Why?
|
Biopsy | 2 | 2013 | 6793 | 0.060 |
Why?
|
Fatigue | 3 | 2018 | 1557 | 0.060 |
Why?
|
Nurses | 1 | 2014 | 2501 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 13014 | 0.060 |
Why?
|
Dietary Carbohydrates | 1 | 2009 | 896 | 0.060 |
Why?
|
Ascitic Fluid | 1 | 2004 | 189 | 0.060 |
Why?
|
Minors | 1 | 2004 | 59 | 0.060 |
Why?
|
Desensitization, Immunologic | 1 | 2009 | 558 | 0.050 |
Why?
|
Young Adult | 7 | 2023 | 60066 | 0.050 |
Why?
|
Professional-Family Relations | 1 | 2007 | 501 | 0.050 |
Why?
|
Retinal Cone Photoreceptor Cells | 1 | 2005 | 183 | 0.050 |
Why?
|
Genes, MDR | 1 | 2003 | 36 | 0.050 |
Why?
|
Religion and Medicine | 1 | 2005 | 161 | 0.050 |
Why?
|
Drug Costs | 1 | 2011 | 1195 | 0.050 |
Why?
|
Registries | 1 | 1999 | 8375 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12543 | 0.050 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2003 | 260 | 0.050 |
Why?
|
Phosphoglycerate Kinase | 1 | 2002 | 66 | 0.050 |
Why?
|
Interleukin-6 | 3 | 2003 | 3228 | 0.050 |
Why?
|
Self Report | 1 | 2014 | 3773 | 0.050 |
Why?
|
Pain Measurement | 2 | 2005 | 3583 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.050 |
Why?
|
Tubulin | 2 | 2003 | 695 | 0.050 |
Why?
|
Oxidative Stress | 1 | 2013 | 3139 | 0.050 |
Why?
|
Akathisia, Drug-Induced | 1 | 2002 | 66 | 0.050 |
Why?
|
Humanism | 1 | 2003 | 84 | 0.050 |
Why?
|
Diabetes Complications | 1 | 2009 | 1320 | 0.050 |
Why?
|
Psychology | 1 | 2004 | 353 | 0.050 |
Why?
|
Constipation | 2 | 2018 | 570 | 0.050 |
Why?
|
Christianity | 1 | 2002 | 53 | 0.050 |
Why?
|
Germany | 1 | 2004 | 883 | 0.050 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1656 | 0.050 |
Why?
|
Abdominal Pain | 2 | 2023 | 1070 | 0.050 |
Why?
|
Biological Availability | 1 | 2002 | 389 | 0.050 |
Why?
|
Nebulizers and Vaporizers | 1 | 2002 | 139 | 0.050 |
Why?
|
Taxoids | 1 | 2004 | 667 | 0.050 |
Why?
|
Risk Assessment | 5 | 2015 | 24315 | 0.050 |
Why?
|
Chromosomes, Human, X | 1 | 2003 | 320 | 0.050 |
Why?
|
Adenosine Diphosphate | 1 | 2022 | 422 | 0.050 |
Why?
|
Half-Life | 1 | 2002 | 651 | 0.050 |
Why?
|
Gastrointestinal Agents | 1 | 2005 | 511 | 0.040 |
Why?
|
GTP Phosphohydrolases | 1 | 2024 | 525 | 0.040 |
Why?
|
Age of Onset | 1 | 2008 | 3347 | 0.040 |
Why?
|
Informed Consent | 1 | 2007 | 1010 | 0.040 |
Why?
|
Social Conditions | 1 | 2001 | 121 | 0.040 |
Why?
|
Radiography | 2 | 2004 | 6983 | 0.040 |
Why?
|
Nurse's Role | 1 | 2002 | 188 | 0.040 |
Why?
|
Negotiating | 1 | 2002 | 152 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 18065 | 0.040 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2020 | 98 | 0.040 |
Why?
|
Ovary | 1 | 2004 | 965 | 0.040 |
Why?
|
Electronic Mail | 1 | 2002 | 215 | 0.040 |
Why?
|
Bone Neoplasms | 2 | 2003 | 2565 | 0.040 |
Why?
|
Spirituality | 1 | 2005 | 430 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2022 | 428 | 0.040 |
Why?
|
Age Factors | 3 | 2020 | 18412 | 0.040 |
Why?
|
Health Status Indicators | 1 | 2005 | 969 | 0.040 |
Why?
|
Education, Medical, Continuing | 1 | 2005 | 829 | 0.040 |
Why?
|
Marketing of Health Services | 1 | 2001 | 151 | 0.040 |
Why?
|
Family Relations | 1 | 2002 | 318 | 0.040 |
Why?
|
Maytansine | 1 | 2020 | 88 | 0.040 |
Why?
|
Drug Industry | 1 | 2006 | 791 | 0.040 |
Why?
|
Hemangioendothelioma | 1 | 2000 | 112 | 0.040 |
Why?
|
Viscera | 1 | 1999 | 138 | 0.040 |
Why?
|
Disease Management | 2 | 2020 | 2536 | 0.040 |
Why?
|
Child Behavior | 1 | 2005 | 864 | 0.040 |
Why?
|
Administration, Inhalation | 1 | 2002 | 1169 | 0.040 |
Why?
|
Pain, Intractable | 1 | 2000 | 132 | 0.040 |
Why?
|
Attitude | 1 | 2004 | 771 | 0.040 |
Why?
|
Infusions, Parenteral | 1 | 2019 | 396 | 0.040 |
Why?
|
Pulmonary Ventilation | 1 | 2000 | 375 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2002 | 693 | 0.040 |
Why?
|
Retinal Diseases | 1 | 2005 | 710 | 0.040 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2021 | 287 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2005 | 1741 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7453 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2011 | 5536 | 0.040 |
Why?
|
Hospitals, General | 1 | 2003 | 809 | 0.040 |
Why?
|
Body Weight | 1 | 2009 | 4627 | 0.040 |
Why?
|
Neoplasm Metastasis | 3 | 2014 | 4912 | 0.040 |
Why?
|
Mullerian Ducts | 1 | 2019 | 203 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2001 | 1587 | 0.040 |
Why?
|
Mucositis | 1 | 2018 | 108 | 0.040 |
Why?
|
Isoenzymes | 1 | 2002 | 1688 | 0.040 |
Why?
|
Receptor, erbB-2 | 3 | 2022 | 2603 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2017 | 67 | 0.040 |
Why?
|
Organophosphorus Compounds | 1 | 1998 | 211 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2001 | 1888 | 0.040 |
Why?
|
Point Mutation | 1 | 2003 | 1596 | 0.040 |
Why?
|
Area Under Curve | 1 | 2001 | 1643 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2001 | 681 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 1999 | 330 | 0.040 |
Why?
|
Chemokine CCL2 | 1 | 1999 | 605 | 0.030 |
Why?
|
Advance Directives | 1 | 1999 | 249 | 0.030 |
Why?
|
Public Opinion | 1 | 2001 | 486 | 0.030 |
Why?
|
Terminally Ill | 1 | 1999 | 240 | 0.030 |
Why?
|
Resuscitation Orders | 1 | 1999 | 271 | 0.030 |
Why?
|
Ovariectomy | 1 | 2019 | 613 | 0.030 |
Why?
|
Life Change Events | 1 | 2002 | 960 | 0.030 |
Why?
|
Child, Preschool | 3 | 2022 | 42669 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2001 | 1338 | 0.030 |
Why?
|
Risk Factors | 3 | 2015 | 74944 | 0.030 |
Why?
|
Family | 2 | 2005 | 3209 | 0.030 |
Why?
|
Placebos | 1 | 2000 | 1667 | 0.030 |
Why?
|
Adolescent Behavior | 1 | 2005 | 1186 | 0.030 |
Why?
|
Conscious Sedation | 1 | 2000 | 534 | 0.030 |
Why?
|
Pleural Neoplasms | 1 | 2001 | 612 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 2862 | 0.030 |
Why?
|
Postmenopause | 1 | 2004 | 2518 | 0.030 |
Why?
|
Drug Synergism | 1 | 2019 | 1760 | 0.030 |
Why?
|
Cocaine-Related Disorders | 1 | 1999 | 458 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2000 | 1062 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2003 | 1997 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2011 | 11095 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2010 | 15948 | 0.030 |
Why?
|
Insulin Resistance | 1 | 2009 | 3986 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2001 | 1271 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2016 | 416 | 0.030 |
Why?
|
Retrospective Studies | 8 | 2020 | 81762 | 0.030 |
Why?
|
Psychotherapy | 1 | 2004 | 1654 | 0.030 |
Why?
|
Cohort Studies | 5 | 2024 | 41754 | 0.030 |
Why?
|
Mesothelioma | 1 | 2001 | 811 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39348 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2000 | 2107 | 0.030 |
Why?
|
HIV Infections | 2 | 1999 | 17569 | 0.030 |
Why?
|
DNA, Complementary | 3 | 2003 | 1989 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2001 | 1895 | 0.030 |
Why?
|
Anorexia | 1 | 2014 | 153 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2008 | 17140 | 0.030 |
Why?
|
Internationality | 1 | 2019 | 1008 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 879 | 0.030 |
Why?
|
Prospective Studies | 4 | 2013 | 54926 | 0.030 |
Why?
|
Hodgkin Disease | 1 | 2001 | 1384 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2014 | 300 | 0.030 |
Why?
|
Spinal Neoplasms | 1 | 1999 | 715 | 0.020 |
Why?
|
Neuroendocrine Tumors | 1 | 1998 | 659 | 0.020 |
Why?
|
Immunoconjugates | 1 | 2020 | 975 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2009 | 8647 | 0.020 |
Why?
|
Pedigree | 1 | 2000 | 4539 | 0.020 |
Why?
|
Hypnotics and Sedatives | 1 | 2000 | 1191 | 0.020 |
Why?
|
Child | 3 | 2005 | 80917 | 0.020 |
Why?
|
Acute Disease | 1 | 2002 | 7243 | 0.020 |
Why?
|
Integrin alpha5beta1 | 1 | 2011 | 36 | 0.020 |
Why?
|
Blotting, Northern | 2 | 2003 | 1550 | 0.020 |
Why?
|
Vomiting | 1 | 2014 | 655 | 0.020 |
Why?
|
Remission Induction | 1 | 2016 | 2410 | 0.020 |
Why?
|
Verapamil | 2 | 2002 | 242 | 0.020 |
Why?
|
Collagen | 1 | 1999 | 2643 | 0.020 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2006 | 631 | 0.020 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2011 | 193 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2003 | 2517 | 0.020 |
Why?
|
Disclosure | 1 | 1995 | 755 | 0.020 |
Why?
|
Hypertension | 1 | 2010 | 8616 | 0.020 |
Why?
|
Rupture, Spontaneous | 1 | 2010 | 365 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2010 | 20760 | 0.020 |
Why?
|
Health Status | 2 | 2014 | 4091 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2002 | 3049 | 0.020 |
Why?
|
Tumor Cells, Cultured | 3 | 2002 | 6124 | 0.020 |
Why?
|
Reoperation | 1 | 1999 | 4329 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2001 | 3488 | 0.020 |
Why?
|
Dermatologic Agents | 1 | 2012 | 313 | 0.020 |
Why?
|
Oligopeptides | 1 | 2013 | 1194 | 0.020 |
Why?
|
Health Personnel | 1 | 2002 | 3385 | 0.020 |
Why?
|
Emotions | 1 | 2000 | 2767 | 0.020 |
Why?
|
Suicide | 1 | 1999 | 1606 | 0.020 |
Why?
|
Psychological Tests | 1 | 2010 | 643 | 0.020 |
Why?
|
Diarrhea | 1 | 2014 | 1320 | 0.020 |
Why?
|
Reproduction | 1 | 2011 | 646 | 0.020 |
Why?
|
Skin Tests | 1 | 2009 | 639 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2010 | 2560 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3800 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1999 | 5151 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2003 | 4423 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2004 | 26422 | 0.020 |
Why?
|
Pelvis | 1 | 2010 | 736 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1721 | 0.020 |
Why?
|
Rats | 1 | 2001 | 23760 | 0.020 |
Why?
|
Animals | 2 | 2011 | 169246 | 0.020 |
Why?
|
Lymphedema | 1 | 2011 | 527 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 4580 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 1999 | 2973 | 0.010 |
Why?
|
Transfection | 2 | 2003 | 5755 | 0.010 |
Why?
|
Peritoneal Lavage | 1 | 2004 | 31 | 0.010 |
Why?
|
Esophageal Neoplasms | 1 | 1994 | 1668 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 1994 | 1481 | 0.010 |
Why?
|
Rhodopsin | 1 | 2005 | 198 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2005 | 424 | 0.010 |
Why?
|
Anemia | 1 | 2013 | 1514 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3436 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9669 | 0.010 |
Why?
|
Pregnancy | 2 | 2003 | 30256 | 0.010 |
Why?
|
Peritoneum | 1 | 2004 | 230 | 0.010 |
Why?
|
Mass Screening | 1 | 1999 | 5458 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2003 | 325 | 0.010 |
Why?
|
Electroretinography | 1 | 2005 | 524 | 0.010 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2005 | 563 | 0.010 |
Why?
|
Disability Evaluation | 1 | 2010 | 1835 | 0.010 |
Why?
|
Visual Field Tests | 1 | 2005 | 415 | 0.010 |
Why?
|
Tetrazolium Salts | 1 | 2002 | 92 | 0.010 |
Why?
|
Mitoxantrone | 1 | 2002 | 148 | 0.010 |
Why?
|
Melanoma | 1 | 2000 | 5706 | 0.010 |
Why?
|
Infant | 1 | 2004 | 36535 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2000 | 5717 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2010 | 2430 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2003 | 563 | 0.010 |
Why?
|
Transcription Factors | 1 | 2000 | 12168 | 0.010 |
Why?
|
Multigene Family | 1 | 2003 | 1081 | 0.010 |
Why?
|
Testis | 1 | 2003 | 783 | 0.010 |
Why?
|
Motivation | 1 | 2010 | 2020 | 0.010 |
Why?
|
Caspase 3 | 1 | 2002 | 730 | 0.010 |
Why?
|
Gene Library | 1 | 2002 | 1064 | 0.010 |
Why?
|
Phenotype | 3 | 2003 | 16726 | 0.010 |
Why?
|
Specimen Handling | 1 | 2004 | 708 | 0.010 |
Why?
|
Collagen Type XVIII | 1 | 1999 | 52 | 0.010 |
Why?
|
Crack Cocaine | 1 | 1999 | 33 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2010 | 2783 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2010 | 5315 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 2828 | 0.010 |
Why?
|
Telomerase | 1 | 2004 | 751 | 0.010 |
Why?
|
Caspases | 1 | 2002 | 882 | 0.010 |
Why?
|
Lung | 1 | 1997 | 10099 | 0.010 |
Why?
|
Calcium-Binding Proteins | 1 | 2003 | 1083 | 0.010 |
Why?
|
Endostatins | 1 | 1999 | 167 | 0.010 |
Why?
|
Suicide, Assisted | 1 | 1999 | 68 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3239 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21538 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2011 | 3589 | 0.010 |
Why?
|
Pregnancy, Multiple | 1 | 1999 | 216 | 0.010 |
Why?
|
Visual Fields | 1 | 2005 | 1065 | 0.010 |
Why?
|
Stem Cells | 1 | 2011 | 3537 | 0.010 |
Why?
|
Biological Transport | 1 | 2002 | 2085 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2003 | 1744 | 0.010 |
Why?
|
Cultural Characteristics | 1 | 1999 | 250 | 0.010 |
Why?
|
Twins | 1 | 1999 | 341 | 0.010 |
Why?
|
Liposomes | 1 | 2001 | 790 | 0.010 |
Why?
|
Vincristine | 1 | 1999 | 1040 | 0.010 |
Why?
|
Risk | 1 | 2009 | 9613 | 0.010 |
Why?
|
Exons | 1 | 2003 | 2394 | 0.010 |
Why?
|
Spouses | 1 | 1999 | 286 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2003 | 2732 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2002 | 3590 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2006 | 2784 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7852 | 0.010 |
Why?
|
Personality | 1 | 1999 | 559 | 0.010 |
Why?
|
Epirubicin | 1 | 1994 | 82 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2003 | 3800 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3814 | 0.010 |
Why?
|
Thiazoles | 1 | 2002 | 1542 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4473 | 0.010 |
Why?
|
Blotting, Western | 1 | 2002 | 5027 | 0.010 |
Why?
|
Interferon-alpha | 1 | 1998 | 910 | 0.010 |
Why?
|
Thoracic Vertebrae | 1 | 1999 | 613 | 0.010 |
Why?
|
Blood Pressure | 1 | 2010 | 8543 | 0.010 |
Why?
|
Genomics | 1 | 2009 | 5926 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2009 | 9538 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2003 | 6082 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9495 | 0.010 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 1995 | 520 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2002 | 3402 | 0.010 |
Why?
|
Cell Survival | 1 | 2002 | 5777 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2003 | 4786 | 0.010 |
Why?
|
Epithelium | 1 | 1997 | 1607 | 0.010 |
Why?
|
RNA | 1 | 2002 | 2720 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2003 | 3445 | 0.010 |
Why?
|
Minority Groups | 1 | 1999 | 1216 | 0.010 |
Why?
|
Drug Monitoring | 1 | 1996 | 964 | 0.010 |
Why?
|
Cesarean Section | 1 | 1999 | 1425 | 0.010 |
Why?
|
Base Sequence | 1 | 2000 | 12421 | 0.010 |
Why?
|
Lymphoma | 1 | 1999 | 1898 | 0.010 |
Why?
|
Lumbar Vertebrae | 1 | 1999 | 1885 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1998 | 6514 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 14729 | 0.000 |
Why?
|
Diagnostic Errors | 1 | 1995 | 1281 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 2000 | 17622 | 0.000 |
Why?
|
Laser Therapy | 1 | 1994 | 1107 | 0.000 |
Why?
|
Pregnancy Complications, Infectious | 1 | 1999 | 2185 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2004 | 22291 | 0.000 |
Why?
|